Innovative Targeting Solutions Inc. (ITS) announced a research agreement with Eli Lilly and Company. Under the agreement, Innovative Targeting Solutions' will utilize its proprietary HuTARG research platform to potentially discover first in class antibody drug candidates. The HuTARG protein engineering platform allows one to directly isolate and engineer antibodies based on functional activity at scales not attainable with any other technology.